Genome-wide CRISPR/Cas9 screening identifies the N-terminal acetyltransferase NAA60 to facilitate cis- and carboplatin drug sensitivity, most likely by neutralizing Nt acetylation of the LRRC8A/D VRAC subunits regulating substrate permeability.
- Carmen Alexandra Widmer
- Anna Moyseos
- Sven Rottenberg
